Frizziero Antonio, Maffulli Nicola, Masiero Stefano, Frizziero Luigi
Department of Physical and Rehabilitation Medicine, University of Padova, Italy.
Queen Mary University of London Centre for Sports and Exercise Medicine Mile End Hospital Mann Ward, London, UK; Head of Department of Physical and Rehabilitation Medicine, University of Salerno, Azienda Ospedaliera San Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy.
Muscles Ligaments Tendons J. 2014 Jul 14;4(2):256-61. eCollection 2014 Apr.
this retrospective open label study evaluates the efficacy and tolerability of intra-articular injections of Hyaluronic Acid (HA) (MW 500-730 KDa - Hyalgan®) for the treatment of pain and disability of trapeziometacarpal joint osteoarthritis (TMCJ OA).
fifty eight patients, 50 females (86%) and 8 male (14%), aged between 40-75 years, suffering from TMCJ OA according to Kellgren-Laurence grades 2-3 on standard plain radiography, were included. Patients with known inflammatory arthritis, previous thumb trauma and intra-articular (i.a.) injections with corticosteroids were excluded. Primary endpoints were: pain (VAS), NSAID intake, radial and palmar ab-/adduction, pinch strength. All patients received an i.a. injection of 0.8 mL of HA (MW 500-730 KDa) once weekly for three weeks. Control examinations were carried out at 1, 3, and 6 months.
intra-articular HA injections have significantly reduced spontaneous and provoked pain and improved hand mobility. At 1,3, and 6 months from baseline, the spontaneous and provoked pain revealed a statistically significant improvement (p<0,0001). NSAID's intake evidenced a statistically significant reduction against baseline (p<0.017). The adverse events (21%) were related to local symptoms such as pain during or following HA administration.
this study shows that i.a. HA injections for TMCJ OA can induce a significant improvement of function associated to stiffness decrease and pain relief.
本回顾性开放标签研究评估了关节腔内注射透明质酸(HA)(分子量500 - 730 kDa - 海乐妙®)治疗第一掌腕关节骨关节炎(TMCJ OA)疼痛和功能障碍的疗效及耐受性。
纳入58例患者,其中50例女性(86%),8例男性(14%),年龄在40 - 75岁之间,根据标准X线平片Kellgren - Laurence分级为2 - 3级的TMCJ OA患者。排除已知患有炎性关节炎、既往有拇指外伤史以及曾接受关节腔内注射皮质类固醇的患者。主要终点指标为:疼痛(视觉模拟评分法[VAS])、非甾体抗炎药摄入量、桡侧和掌侧外展/内收、捏力。所有患者每周接受一次0.8 mL的HA(分子量500 - 730 kDa)关节腔内注射,共注射三周。在1、3和6个月时进行对照检查。
关节腔内注射HA显著减轻了自发痛和激发痛,并改善了手部活动度。与基线相比,在1、3和6个月时,自发痛和激发痛均有统计学意义的改善(p < 0.0001)。非甾体抗炎药的摄入量与基线相比有统计学意义的减少(p < 0.017)。不良事件发生率为21%,与局部症状有关,如HA注射期间或之后的疼痛。
本研究表明,关节腔内注射HA治疗TMCJ OA可显著改善功能,减轻僵硬并缓解疼痛。